
## Karin Potthoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7667622/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. Cancer Treatment Reviews, 2017, 52, 91-104.	7.7	398
2	Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. Journal of the National Cancer Institute, 2018, 110, 1190-1200.	6.3	72
3	Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. British Journal of Sports Medicine, 2019, 53, 812-812.	6.7	67
4	Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months followâ€up. International Journal of Cancer, 2018, 142, 1148-1157.	5.1	47
5	Factors influencing participation in a randomized controlled resistance exercise intervention study in breast cancer patients during radiotherapy. BMC Cancer, 2015, 15, 186.	2.6	42
6	Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). European Journal of Haematology, 2018, 101, 766-773.	2.2	10
7	Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR. Current Medical Research and Opinion, 2019, 35, 1127-1138.	1.9	9
8	Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials. Leukemia Research, 2018, 68, 90-97.	0.8	6
9	Prophylaxis of chemotherapyâ€induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with nonâ€Hodgkin lymphoma (NADIR study). European Journal of Haematology, 2019, 102, 174-181.	2.2	6
10	Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma (R/RMM): Final results of the nonâ€interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. European Journal of Haematology, 2021, , .	2.2	6
11	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials ( <scp>LICC</scp> , <scp>CELIM</scp> , <scp>FIRE</scp> â€3). International Journal of Cancer, 2022, 150, 1341-1349.	5.1	6
12	Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients. Supportive Care in Cancer, 2021, 29, 6633-6643.	2.2	5
13	Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. BMC Cancer, 2020. 20. 286.	2.6	3
14	Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies. Oncology Research and Treatment, 2021, 44, 1-9.	1.2	1
15	Effects of resistance training on fatigue and quality of life in breast cancer patients undergoing radiotherapy Journal of Clinical Oncology, 2014, 32, 9534-9534.	1.6	1
16	Reversible posterior leucoencephalopathy syndrome (RPLS) associated with pazopanib Journal of Clinical Oncology, 2013, 31, e15574-e15574.	1.6	0